SAN MATEO, Calif., Nov. 3 Top-line preliminary data from aPhase II/III clinical trial of Corthera's investigational drug relaxin for thetreatment of acute heart failure will be presented next week at a satellitesymposium at the American Heart Association's (AHA) Scientific Sessions 2008in New Orleans.
John R. Teerlink, M.D., Professor of Medicine, University of CaliforniaSan Francisco, will present the data from the multicenter, internationalPre/RELAX-AHF study as part of a symposium entitled "Tailoring Therapy toPresentation" that will focus on new approaches to the treatment of acuteheart failure. The symposium will take place from 6 a.m. CST to 8 a.m. CST onMonday, Nov. 10, in the Grand Ballroom of the Sheraton New Orleans Hotel.
According to the AHA, heart failure is a costly syndrome contributing tomore than 3 million hospitalizations each year in the U.S. The great majorityof patients with acute heart failure have fluid accumulation in the lungs(congestion) that causes shortness of breath and other complications. Forthese patients, the current standard of care includes diuretics andvasodilators. Both of these classes of agents have been associated with renalimpairment, hypotension and adverse outcomes.
Relaxin is a naturally occurring peptide hormone that acts as a systemicand renal vasodilator. Elevated levels of relaxin modulate increases in renaland cardiac function that meet the increased hemodynamic demands of pregnancy.Consistent with this natural role of the hormone, pharmaceuticallymanufactured relaxin has been shown to have these effects in multiple humanstudies of men and non-pregnant women. Data from a pilot study in patientswith heart failure support the expectation that these effects may bebeneficial in relieving the signs and symptoms of heart failure.
Corthera Inc. is a biopharmaceutical company committed to acquiring,developing and commercializing therapies for illnesses in the acute caresetting. Corthera's lead product candidate, relaxin, is currently beingevaluated in clinical trials for acute heart failure. Corthera has worldwiderights to develop and commercialize relaxin.
About the Satellite Symposium
Dr. Teerlink is the chair of the symposium and co-principal investigatorof the Pre/RELAX-AHF study. Additional speakers will include Dr. Marco Metra,associate professor of cardiology, Department of Experimental and AppliedMedicine, University of Brescia, Italy, and Dr. Gregg Fonarow, professor ofmedicine, UCLA School of Medicine. Dr. Metra is also co-principalinvestigator of the Pre/RELAX-AHF Study. Additional symposium information canbe found at:http://www.thrombo.net/tailoring-therapy/tailoring-therapy.pdf Contact: Andreas Marathovouniotis or Ian Stone Russo Partners 212.845.4235 or 619.814.3510 firstname.lastname@example.org email@example.com